Moore Zena Eh, Corcoran Meave A, Patton Declan
School of Nursing & Midwifery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Department of Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland.
Cochrane Database Syst Rev. 2020 Jul 17;7(7):CD011378. doi: 10.1002/14651858.CD011378.pub2.
Foot ulcers in people with diabetes are non-healing, or poorly healing, partial, or full-thickness wounds below the ankle. These ulcers are common, expensive to manage and cause significant morbidity and mortality. The presence of a wound has an impact on nutritional status because of the metabolic cost of repairing tissue damage, in addition to the nutrient losses via wound fluid. Nutritional interventions may improve wound healing of foot ulcers in people with diabetes.
To evaluate the effects of nutritional interventions on the healing of foot ulcers in people with diabetes.
In March 2020 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta-analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting.
We included randomised controlled trials (RCTs) that evaluated the effect of nutritional interventions on the healing of foot ulcers in people with diabetes.
Two review authors, working independently, assessed included RCTs for their risk of bias and rated the certainty of evidence using GRADE methodology, using pre-determined inclusion and quality criteria.
We identified nine RCTs (629 participants). Studies explored oral nutritional interventions as follows: a protein (20 g protein per 200 mL bottle), 1 kcal/mL ready-to-drink, nutritional supplement with added vitamins, minerals and trace elements; arginine, glutamine and β-hydroxy-β-methylbutyrate supplement; 220 mg zinc sulphate supplements; 250 mg magnesium oxide supplements; 1000 mg/day omega-3 fatty acid from flaxseed oil; 150,000 IU of vitamin D, versus 300,000 IU of vitamin D; 250 mg magnesium oxide plus 400 IU vitamin E and 50,000 IU vitamin D supplements. The comparator in eight studies was placebo, and in one study a different dose of vitamin D. Eight studies reported the primary outcome measure of ulcer healing; only two studies reported a measure of complete healing. Six further studies reported measures of change in ulcer dimension, these studies reported only individual parameters of ulcer dimensions (i.e. length, width and depth) and not change in ulcer volume. All of the evidence identified was very low certainty. We downgraded it for risks of bias, indirectness and imprecision. It is uncertain whether oral nutritional supplement with 20 g protein per 200 mL bottle, 1 kcal/mL, nutritional supplement with added vitamins, minerals and trace elements, increases the proportion of ulcers healed at six months more than placebo (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.42 to 1.53). It is also uncertain whether arginine, glutamine and β-hydroxy-β-methylbutyrate supplement increases the proportion of ulcers healed at 16 weeks compared with placebo (RR 1.09, 95% CI 0.85 to 1.40). It is uncertain whether the following interventions change parameters of ulcer dimensions over time when compared with placebo; 220 mg zinc sulphate supplement containing 50 mg elemental zinc, 250 mg magnesium oxide supplement, 1000 mg/day omega-3 fatty acid from flaxseed oil supplement, magnesium and vitamin E co-supplementation and vitamin D supplementation. It is also uncertain whether 150,000 IU of vitamin D, impacts ulcer dimensions when compared with 300,000 IU of vitamin D. Two studies explored some of the secondary outcomes of interest for this review. It is uncertain whether oral nutritional supplement with 20 g protein per 200 mL bottle, 1 kcal/mL, nutritional supplement with added vitamins, minerals and trace elements, reduces the number of deaths (RR 0.96, 95% CI 0.06 to 14.60) or amputations (RR 4.82, 95% CI 0.24 to 95.88) more than placebo. It is uncertain whether arginine, glutamine and β-hydroxy-β-methylbutyrate supplement increases health-related quality of life at 16 weeks more than placebo (MD -0.03, 95% CI -0.09 to 0.03). It is also uncertain whether arginine, glutamine and β-hydroxy-β-methylbutyrate supplement reduces the numbers of new ulcers (RR 1.04, 95% CI 0.71 to 1.51), or amputations (RR 0.66, 95% CI 0.16 to 2.69) more than placebo. None of the included studies reported the secondary outcomes cost of intervention, acceptability of the intervention (or satisfaction) with respect to patient comfort, length of patient hospital stay, surgical interventions, or osteomyelitis incidence. One study exploring the impact of arginine, glutamine and β-hydroxy-β-methylbutyrate supplement versus placebo did not report on any relevant outcomes.
AUTHORS' CONCLUSIONS: Evidence for the impact of nutritional interventions on the healing of foot ulcers in people with diabetes compared with no nutritional supplementation, or compared with a different dose of nutritional supplementation, remains uncertain, with eight studies showing no clear benefit or harm. It is also uncertain whether there is a difference in rates of adverse events, amputation rate, development of new foot ulcers, or quality of life, between nutritional interventions and placebo. More research is needed to clarify the impact of nutritional interventions on the healing of foot ulcers in people with diabetes.
糖尿病患者足部溃疡是指踝关节以下无法愈合、愈合不佳、部分或全层的伤口。这些溃疡很常见,治疗费用高昂,会导致严重的发病率和死亡率。伤口的存在除了会通过伤口渗出液造成营养物质流失外,还会因修复组织损伤的代谢成本而影响营养状况。营养干预可能会改善糖尿病患者足部溃疡的愈合情况。
评估营养干预对糖尿病患者足部溃疡愈合的影响。
2020年3月,我们检索了Cochrane伤口专业注册库、Cochrane对照试验中心注册库(CENTRAL)、Ovid MEDLINE、Ovid Embase和EBSCO CINAHL Plus。我们还检索了临床试验注册库以查找正在进行和未发表的研究,并浏览了相关纳入研究以及综述、荟萃分析和卫生技术报告的参考文献列表,以识别其他研究。对语言、出版日期或研究背景没有限制。
我们纳入了评估营养干预对糖尿病患者足部溃疡愈合影响的随机对照试验(RCT)。
两位综述作者独立评估纳入的RCT的偏倚风险,并使用GRADE方法,根据预先确定的纳入标准和质量标准对证据的确定性进行评级。
我们识别出9项RCT(629名参与者)。研究探讨的口服营养干预措施如下:一种每200毫升含20克蛋白质、每毫升含1千卡、添加了维生素、矿物质和微量元素的即饮型营养补充剂;精氨酸、谷氨酰胺和β-羟基-β-甲基丁酸补充剂;220毫克硫酸锌补充剂;250毫克氧化镁补充剂;每天1000毫克来自亚麻籽油的ω-3脂肪酸;150,000国际单位维生素D与300,000国际单位维生素D对比;250毫克氧化镁加400国际单位维生素E和50,000国际单位维生素D补充剂。8项研究中的对照物为安慰剂,1项研究中的对照物为不同剂量的维生素D。8项研究报告了溃疡愈合的主要结局指标;只有2项研究报告了完全愈合的指标。另外6项研究报告了溃疡尺寸变化的指标,这些研究仅报告了溃疡尺寸的个别参数(即长度、宽度和深度),而非溃疡体积的变化。所有识别出的证据确定性都非常低。我们因其存在偏倚风险、间接性和不精确性而对其进行了降级。每200毫升含20克蛋白质、每毫升含1千卡、添加了维生素、矿物质和微量元素的口服营养补充剂相比安慰剂,在六个月时使溃疡愈合比例增加的情况尚不确定(风险比(RR)0.80,95%置信区间(CI)0.42至1.53)。精氨酸、谷氨酰胺和β-羟基-β-甲基丁酸补充剂相比安慰剂,在16周时使溃疡愈合比例增加的情况也不确定(RR 1.09,95%CI 0.85至1.40)。与安慰剂相比,以下干预措施随时间推移是否会改变溃疡尺寸参数尚不确定:含50毫克元素锌的220毫克硫酸锌补充剂、250毫克氧化镁补充剂、每天1000毫克来自亚麻籽油的ω-3脂肪酸补充剂、镁和维生素E联合补充剂以及维生素D补充剂。与300,000国际单位维生素D相比,150,000国际单位维生素D是否会影响溃疡尺寸也不确定。2项研究探讨了本综述感兴趣的一些次要结局。每200毫升含20克蛋白质、每毫升含1千卡、添加了维生素、矿物质和微量元素的口服营养补充剂相比安慰剂,是否能降低死亡人数(RR 0.96,95%CI 0.06至14.60)或截肢人数(RR 4.82,95%CI 0.24至95.88)尚不确定。精氨酸、谷氨酰胺和β-羟基-β-甲基丁酸补充剂相比安慰剂,在16周时是否能提高健康相关生活质量也不确定(MD -0.03,95%CI -0.09至0.03)。精氨酸、谷氨酰胺和β-羟基-β-甲基丁酸补充剂相比安慰剂,是否能减少新溃疡数量(RR 1.04,95%CI 0.71至1.51)或截肢人数(RR 0.66,95%CI 0.16至2.69)也不确定。纳入的研究均未报告干预措施的次要结局成本、干预措施的可接受性(或满意度)、患者舒适度、患者住院时间、手术干预或骨髓炎发病率。一项探讨精氨酸、谷氨酰胺和β-羟基-β-甲基丁酸补充剂与安慰剂对比影响的研究未报告任何相关结局。
与不进行营养补充或与不同剂量的营养补充相比,营养干预对糖尿病患者足部溃疡愈合影响的证据仍然不确定,8项研究未显示出明显的益处或危害。营养干预与安慰剂在不良事件发生率、截肢率、新足部溃疡的发生或生活质量方面是否存在差异也不确定。需要更多研究来阐明营养干预对糖尿病患者足部溃疡愈合的影响。